Gang liu | Cancer | Best Researcher Award

Posted on by PencisLeave a Comment on Gang liu | Cancer | Best Researcher Award

Prof Gang liu | Cancer | Best Researcher Award

Gansu Provincial Center for Disease Control and Prevention | China

Author Profile

Scopus

Gang Liu: Pioneer in Radiobiology and Preventive Medicine āš›ļø

EARLY ACADEMIC PURSUITS šŸŽ“

Gang Liu began his academic journey at Lanzhou University, where he pursued a PhD in preventive medicine. His graduation in 1997 marked the beginning of a career dedicated to understanding the impacts of radiation on health. His academic training in preventive medicine provided the foundation for his future contributions to radiobiology and public health, particularly in the context of disease control and prevention.

PROFESSIONAL ENDEAVORS šŸ¢

After obtaining his PhD, Gang Liu embarked on a distinguished career at the Gansu Provincial Center for Disease Control and Prevention. His professional focus has been on the intersection of radiobiology, immunology, and tumor screening. In 2019, his registration as a health physicist signaled a significant milestone. He became the technical lead for a groundbreaking study on low-dose dose-effect relationships, a critical area in radiation therapy and safety. His expertise in radiation protection and therapy has earned him a prominent position within the medical research community.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCERšŸ§¬

Gang Liu's research primarily revolves around radiobiology and radiation protection in therapy. His technological advancements in biological dose estimation are considered cutting-edge within China and recognized internationally. One of his significant contributions was revising the 2011 IAEA Manual based on findings from his studies on radiological sensitivity and dose rates. This revision, coupled with his publications in the FASEB Journal, has made Liu a leading figure in radiation science. His work in chromosomal aberration analysis and developing noninvasive techniques for early-stage cancer screening underscores his innovative approach to medical research.

IMPACT AND INFLUENCE šŸŒ

Gang Liu's influence extends beyond national borders. His research on radiological sensitivity and dose rates, especially in the context of cancer screening and radiation therapy, has set new benchmarks in the field. The international recognition of his work, particularly his advancements in biological dose estimation and contributions to global radiation protection protocols, underscores his importance in radiobiology. His work is used by institutions worldwide to improve radiation safety standards and enhance cancer diagnostic techniques.

ACADEMIC CITATIONS šŸ“š

His pioneering research has been published in prestigious journals such as the FASEB Journal, one of the top international platforms for scientific contributions. The citations of his work in radiological sensitivity, chromosomal aberration analysis, and cancer screening techniques reflect his deep impact on the scientific community, with his methods influencing both practical applications in healthcare and further research.

LEGACY AND FUTURE CONTRIBUTIONS šŸ”¬

Gang Liuā€™s legacy will likely be defined by his leadership in advancing radiation protection technology and cancer screening techniques. As an innovator in radiological health, his influence will continue to grow through future contributions to radiation therapy safety, noninvasive cancer detection, and international health standards. His ongoing work in exploring new methods for biological dose estimation will further establish his standing as a key figure in the evolution of radiation medicine.

NOTABLE PUBLICATIONSĀ šŸ“‘

"Study of Low-Dose Radiation Workers Ionizing Radiation Sensitivity Index and Radiation Dose-Effect Relationship"Ā 

  • Authors: Liu, G., Zhang, R., Li, Y., Liu, Y.Y., Zhang, X.
  • Journal: Health Physics
  • Year: 2022

"Revision of cytogenetic dosimetry in the IAEA manual 2011 based on data about radio-sensitivity and dose-rate findings contributing"Ā 

  • Authors:Liu, G.
  • Journal: FASEB Journal
  • Year: 2022

"Thyroid dose assessments due to inhalation of 131I for nuclear medicine workers"

  • Authors: Liu, G., Li, Y., Zhang, H., Niu, L.M., Zhang, R.
  • Journal: Frontiers in Public Health
  • Year: 2022

"Study of Indicators for Early and Rapid Diagnosis of Radiation Injury Is the Most Important in Patients With Cancer During Radiotherapy"

  • Authors: Liu, G., Niu, L.-M., Wang, L.-Q., Liu, Y.-Y., Zhang, R.
  • Journal: Dose-Response
  • Year: 2020

"Chromosomal aberration analysis: Novel noninvasive techniques for early-stage cancer screening"

  • Authors: Liu, G.
  • Journal: Clinica Chimica Acta
  • Year: 2024

Bruno Fuchs | Sarcoma | Excellence in Innovation

Posted on by PencisLeave a Comment on Bruno Fuchs | Sarcoma | Excellence in Innovation

Prof Dr. Bruno Fuchs | Sarcoma | Excellence in InnovationĀ 

Swiss Sacroma Network | SwitzerlandĀ 

Author Profile

Orcid ID

Bruno Fuchs, MD, PhD šŸŒŸ

Position: Professor and Chair, Sarcoma Center & Swiss Sarcoma Network

Location: Faculty of Health Science & Medicine, University of Lucerne, and LUKS University Hospital, Luzern, Switzerland

Contact: fuchs@sarcoma.surgery

Educational Background šŸŽ“

  • 2022: Guest-Professor, Medical Faculty, University of Lucerne
  • 2010: Extraordinarius, Medical Faculty, University of Zurich
  • 2005: Associate Professor, Medical Faculty, University of Zurich
  • 2004: PhD in Biomedical Sciences (Tumor Biology), Mayo Graduate School, Mayo College of Medicine, Rochester, MN, USA
  • 1996 - 2004: Training and Fellowship in Orthopedic Surgery and Musculoskeletal Oncology at Mayo Clinic, Rochester, MN, USA, and Swiss institutions
  • 1992: MD, Medical Faculty, University of Zurich, Switzerland

Clinical and Research Expertise šŸ”¬

  • Specializes in the surgical treatment of bone and soft tissue tumors in both pediatric and adult patients
  • Focuses on outcome analysis and quality indicators in sarcoma care
  • Engages in predictive outcome analytics for improving sarcoma treatment

Academic Contributions šŸ“š

  • Authored over 200 publications and book chapters
  • Acquired over 10 million Swiss Francs in research funding
  • Active as a reviewer for prestigious journals and grant committees

Contributions and Research Focus on SarcomašŸ†

Fuchs has made profound contributions to the surgical treatment of bone and soft tissue tumors in both pediatric and adult patients. His research is heavily focused on the outcome analysis of sarcoma patients, defining and assessing quality indicators of sarcoma care, and predictive outcome analytics. His work is vital in improving the standards and methodologies employed in sarcoma care, directly impacting patient outcomes and care quality.

Public and Professional Service šŸŒ

  • Founder & Chair of the Swiss Sarcoma Network
  • Founder of the Sarcoma Academy
  • Member of multiple medical societies including SwissOrthopaedics, FMH, and CTOS

Dr. Bruno Fuchs is recognized internationally for his extensive contributions to the field of sarcoma research and treatment. His work continues to shape the future of musculoskeletal oncology.

Notable PublicationsšŸ“‘

"Real-World-Time Data and RCT Synergy: Advancing Personalized Medicine and Sarcoma Care through Digital Innovation"Ā 

  • Authors: Philip Heesen, Georg Schelling, Mirko Birbaumer, Ruben JƤger, Beata Bode, Gabriela Studer, Bruno Fuchs
  • Journal: Cancers
  • Year: 2024

"Improving Sarcoma Outcomes: Target Trial Emulation to Compare the Impact of Unplanned and Planned Resections on the Outcome"Ā 

  • Authors: Timothy T. A. F. Obergfell, Kim N. Nydegger, Philip Heesen, Georg Schelling, Beata Bode-Lesniewska, Gabriela Studer, Bruno Fuchs
  • Journal: Cancers
  • Year: 2024

"Impact of Institutional Practices and Surgical Complexity on Sarcoma Surgery Costs: Driving Efficiency in Value-Based Healthcare"

  • Authors: Georg Schelling, Philip Heesen, Boris Malte Tautermann, Markus Wepf, Barbara Di Federico, Annika Frei, Kim van Oudenaarde, Pietro Giovanoli, Beata Bode-Lesniewska, Gabriela Studer et al.
  • Journal: Cancers
  • Year: 2024

"Development and Validation of the Bone Tumor Surgery Complexity Score"

  • Authors: Annika Frei, Georg Schelling, Philip Heesen, Pietro Giovanoli, Bruno Fuchs
  • Journal: Reports
  • Year: 2024

"Exploring Risk Factors for Predicting 30-Day Postoperative Morbidity in Musculoskeletal Tumor Surgery"

  • Authors: Philip Heesen, Maria Elyes, Jan Domanski, Georg Schelling, Sƶren Kƶnneker, Bruno Fuchs
  • Journal: Journal of Clinical Medicine
  • Year: 2024

Bin Zhang | Gene Mutation | Best Researcher Award

Posted on by PencisLeave a Comment on Bin Zhang | Gene Mutation | Best Researcher Award

Prof Bin Zhang | Gene Mutation | Best Researcher Award

Jining Medical University | China

AUTHOR PROFILE

Scopus

Google Scholar

EARLY ACADEMIC PURSUITS

Bin Zhang's journey into the world of medical research began with a solid foundation in biomedical sciences. His early academic pursuits were marked by a dedication to understanding complex biological systems and a passion for contributing to the field of oncology. This academic dedication led him to become a young expert recognized under the prestigious Taishan Mount Scholars program in China.

PROFESSIONAL ENDEAVORS

In 2018, Bin Zhang was appointed as a researcher at the Affiliated Hospital of Jining Medical University. Here, he established the tumor metabolism research group, assuming the role of Principal Investigator. Under his leadership, the group has grown to focus on four key research directions: the regulatory mechanisms of tumor stem cells, the specificity of tumor biomacromolecules and energy metabolism, the regulation of energy metabolism by oncogenic gene mutations, and the screening of potential drugs targeting tumor metabolism.

CONTRIBUTIONS AND RESEARCH FOCUS ON GENE MUTATION

Bin Zhang's research has significantly advanced the understanding of tumor metabolism. His work has been published in esteemed journals such as Cell Reports Medicine, Biomaterials, Oncogene, Journal of Experimental & Clinical Cancer Research, and Stem Cells. These publications highlight his team's investigations into the intricate mechanisms of tumor biology and potential therapeutic targets. The research group delves into how tumor stem cells are regulated, how tumor biomacromolecules function, and how mutations in oncogenes affect energy metabolism, all of which are crucial for developing new cancer treatments.

IMPACT AND INFLUENCE

The impact of Bin Zhang's research is reflected in the high citation rate of his publications, with over 5000 citations to date and an H-Index of 34. His work has not only contributed valuable knowledge to the scientific community but has also influenced ongoing research and development in tumor metabolism. Furthermore, Bin Zhang has successfully secured ten patents, two of which have been transferred, demonstrating the practical applications and commercial potential of his research findings.

ACADEMIC CITES

Bin Zhang is also an active member of the academic community, serving as a reviewer for several high-impact journals including Stem Cells and Development, EBioMedicine, Stem Cell Research & Therapy, Molecular Carcinogenesis, and the Journal of Clinical Laboratory Medicine. His expertise is sought after in evaluating cutting-edge research and ensuring the quality of publications in these journals.

LEGACY AND FUTURE CONTRIBUTIONS

Bin Zhang's legacy in the field of tumor metabolism is marked by his innovative research and commitment to advancing cancer treatment. Currently, he is the principal investigator of two general projects funded by the National Natural Science Foundation of China, two projects funded by Shandong Province, and two projects funded by the Postdoctoral Foundation of China. His ongoing work promises to uncover new insights and develop novel therapies, continuing to push the boundaries of cancer research

NOTABLE PUBLICATIONS

A roadmap from research to clinical testing of mesenchymal stromal cell exosomes in the treatment of psoriasis 2023(7)

IL-13/IL-13RA2 signaling promotes colorectal cancer stem cell tumorigenesis by inducing ubiquitinated degradation of p53 2023(4)

Therapeutic Efficacy of Mesenchymal Stem/Stromal Cell Small Extracellular Vesicles in Alleviating Arthritic Progression by Restoring Macrophage Balance 2023(1)

Engineered EVs with pathogen proteins: promising vaccine alternatives to LNP-mRNA vaccines 2024

Arachidonic acid released by PIK3CA mutant tumor cells triggers malignant transformation of colonic epithelium by inducing chromatin remodeling 2024